Please use this identifier to cite or link to this item:
http://hdl.handle.net/10397/5764
DC Field | Value | Language |
---|---|---|
dc.contributor | Department of Applied Biology and Chemical Technology | - |
dc.creator | Chan, TH | - |
dc.creator | Lam, WH | - |
dc.creator | Chow, LMC | - |
dc.creator | Dou, QP | - |
dc.creator | Kuhn, DJ | - |
dc.creator | Kazi, A | - |
dc.creator | Wan, SB | - |
dc.creator | Landis-Piwowar, KR | - |
dc.date.accessioned | 2013-05-29T04:20:36Z | - |
dc.date.available | 2013-05-29T04:20:36Z | - |
dc.identifier.uri | http://hdl.handle.net/10397/5764 | - |
dc.language.iso | en | en_US |
dc.rights | Assignee: The Hong Kong Polytechnic University. | en_US |
dc.rights | Assignee: Wayne State University. | en_US |
dc.rights | Assignee: University of South Florida. | en_US |
dc.title | (-)-Epigallocatechin gallate derivatives for inhibiting proteasome | en_US |
dc.type | Patent | en_US |
dc.description.otherinformation | US8193377; US8193377 B2; US8193377B2; US8,193,377; US 8,193,377 B2; 8193377; Appl. No. 11/660,513 | en_US |
dc.description.otherinformation | Inventor name used in this publication: Larry Ming-Cheung Chow | en_US |
dc.description.otherinformation | Inventor name used in this publication: Qing Ping Dou | en_US |
dcterms.abstract | (-)-EGCG, the most abundant catechin, was found to be chemopreventive and anticancer agent. However, (-)-EGCG has at least one limitation: it gives poor bioavailability. This invention provides compounds of generally formulae below, wherein R₁₁, R₁₂, R₁₃, R₂₁, R₂₂, R₂, R₃, and R₄ are each independently selected from the group consisting of --H, and C₁ to C₁₀ acyloxyl group; and R₅ is selected from the group consisting of --H, C₁-C₁₀-alkyl, C₂-C₁₀-alkenyl, C₂-C₁₀-alkynyl, C₃-C₇-cycloalkyl, phenyl, benzyl and C₃-C₇-cycloalkenyl, whereas each of the last mentioned 7 groups can be substituted with any combination of one to six halogen atoms; at least one of R₁₁, R₁₂, R₁₃, R₂₁, R₂₂, R₂, R₃ and R₄ is --H, which were found to be more potent than their non-protected counterparts, which can be used as proteasome inhibitors to reduce tumor cell growth. | - |
dcterms.bibliographicCitation | US Patent 8,193,377 B2. Washington, DC: US Patent and Trademark Office, 2012. | - |
dcterms.issued | 2012-06-05 | - |
dc.description.country | US | - |
dc.description.oa | Version of Record | en_US |
Appears in Collections: | Patent |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
us8193377b2.pdf | 2.06 MB | Adobe PDF | View/Open |
Page views
113
Last Week
2
2
Last month
Citations as of Apr 14, 2024
Downloads
42
Citations as of Apr 14, 2024
Google ScholarTM
Check
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.